Son güncelleme: Ağustos 17, 2026
Bu kök benzeri hücreler kendi kendini yenileyebilir ve tümörü oluşturan kanser hücrelerine neden olmaktan sorumludur..
Karaciğer kanseri dünya çapında kansere bağlı ölümlerin ikinci önde gelen nedenidir.
Yetişkinlerde en sık görülen primer karaciğer kanseri, hepatoselüler karsinom olarak bilinir. (HCC), ve yaklaşık olarak hesaplanıyor 780,000 deaths every year.
Even with advanced surgical treatments or transplantation, the 5-year survival rate for HCC patients remains poor due to frequent recurrence.
Şimdi, ..researchers has demonstrated a potential method for treating advanced liver cancers like HCC. ..Scientists showed that a class of small molecule drugs that target the JAK/STAT signalling pathway could be used to fight against the disease.
“Targeting molecular mechanisms that drive chemoresistance has shown success in clinical trials for other diseases. Öyleyse, such targeted approaches can be potentially useful as adjuvant therapies to improve clinical outcomes of HCC patients.
Inhibiting the JAK/STAT signalling pathway
The JAK/STAT signalling pathway is an important set of proteins that control a wide range of biological functions, including immune responses and cellular development. This pathway typically responds to external cellular cues to turn on specific sets of genes that help cells properly develop or allow the immune system to fight off infections. Gibi, if the JAK/STAT signalling pathway somehow goes awry, it can lead to the formation of tumours.
In their study, the NUS team targeted the JAK/STAT pathway to inhibit its action in tumour formation. They showed that a subpopulation of cancer ‘stem-like’ cells are sensitive to a class of small molecule drugs that inhibit the JAK/STAT pathway. Bu kök benzeri hücreler kendi kendini yenileyebilir ve tümörü oluşturan kanser hücrelerine neden olmaktan sorumludur..
“We can now potentially use small molecule compounds to target these specific small population of cancer stem-like cells that are often the cause of tumour recurrence.”
Small molecule drug candidates effective in reducing cancer progression
The researchers were able to isolate these tumour-initiating cancer cells that are often the culprits of therapy resistance that leads to cancer relapse. They found that an important cancer pathway, known as the JAK/STAT signalling pathway, was enriched in this cancer stem-like population of cells.
Bu çalışmada, JAK/STAT inhibitors targeting cancer stem-like cells were able to effectively reduce cancer progression in preclinical models of liver cancer. The NUS team found that the tumour forming ability was reduced by 50 per cent after drug treatment.
Next steps
These findings provide increased support that JAK/STAT-based therapies targeting cancer stem-like cells are important for more effective treatment outcomes against liver cancer.
r the treatment of other solid cancers.
Hikaye Kaynağı:
ScienceDaily. ScienceDaily, 9 Ekim 2019. <www.sciencedaily.com/releases/2019/10/191009093953.htm>.
Bilimsel Vaka İncelemesi
Mevcut klinik programların olup olmadığını anlamak ister misiniz?, son araştırma gelişmeleri, veya ortaya çıkan yaklaşımlar olabilir kişisel durumunuzla alakalı?
Sorunuzu bilimsel ekibimize gönderin. Birleşik Krallık'taki NBScience merkez ofisi, uluslararası tıp merkezleri ağı genelindeki araştırmaları koordine etmektedir., bilim adamları, ve uzman danışmanlar.
- Sağladığınız bilgilerin gözden geçirilmesi
- İlgili araştırma ve klinik program bilgileri
- Durumunuza odaklanmış net bir yanıt
Hiçbir yükümlülük yok. Sorunuz gizli olarak incelenecektir.
Yalnızca eğitim ve araştırma bilgileri. Bu hizmet tıbbi tavsiye teşkil eder, teşhis, reçete, veya kişiselleştirilmiş tedavi önerisi.
